Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 8/20 | 0.67 |
| ▸ | LPL | P06858 | 2/20 | 0.55 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.55 |
| ▸ | MGLL | Q99685 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | F11 | P03951 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5872608 | 0.82 | ENPP2 (0.72) | ENPP2LPLLIPGMGLLKDM4E | |
| SCHEMBL8832 | 0.80 | ENPP2 (1.00) | ENPP2LPLLIPGMGLLKDM4E | |
| SCHEMBL2503293 | 0.78 | ENPP2 (0.67) | ENPP2LPLLIPGMGLLKDM4E | |
| SCHEMBL723106 | 0.78 | ENPP2 (0.67) | ENPP2LPLLIPGMGLLKDM4E | |
| SCHEMBL257748 | 0.78 | ENPP2 (0.67) | ENPP2LPLLIPGMGLLKDM4E | |
| SCHEMBL692342 | 0.78 | ENPP2 (0.67) | ENPP2LPLLIPGMGLLKDM4E | |
| SCHEMBL14518706 | 0.78 | ENPP2 (0.67) | ENPP2LPLLIPGMGLLKDM4E | |
| SCHEMBL19952 | 0.78 | ENPP2 (0.67) | ENPP2LPLLIPGMGLLKDM4E | |
| SCHEMBL14120836 | 0.78 | ENPP2 (0.67) | ENPP2LPLLIPGMGLLKDM4E | |
| SCHEMBL3952244 | 0.78 | ENPP2 (0.60) | ENPP2LPLLIPGMGLLKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3057963-B1 | PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2019-06-19 | — | — | EP | disclosed |
| EP-2344636-B1 | NOVEL CHIMERIC LIGAND-GATED ION CHANNELS AND METHODS OF USE THEREOF | HUGHES HOWARD MED INST (US) | 2017-12-06 | — | — | EP | disclosed |
| WO-2017066014-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | SUNNYLIFE PHARMA INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-8476308-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8435762-B2 | Chimeric ligand-gated ion channels and methods of use thereof | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2013-05-07 | — | — | US | disclosed |
| US-8299117-B2 | GPR120 receptor agonists and uses thereof | METABOLEX INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20110313003-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2011-12-22 | — | — | US | disclosed |
| EP-2344636-A2 | NOVEL CHIMERIC LIGAND-GATED ION CHANNELS AND METHODS OF USE THEREOF | Howard Hughes Medical Institute (US) | 2011-07-20 | — | — | EP | disclosed |
| EP-2298767-A1 | NITROGENATED BICYCLIC HETEROCYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-20100130420-A1 | NOVEL CHIMERIC LIGAND-GATED ION CHANNELS AND METHODS OF USE THEREOF | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2010-05-27 | — | — | US | disclosed |
| WO-2010042799-A2 | NOVEL CHIMERIC LIGAND-GATED ION CHANNELS AND METHODS OF USE THEREOF | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313003-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | ENPP2 168/4885LPL 517/4885LIPG 363/4885 |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | ENPP2 147/4885LPL 2017/4885LIPG 1774/4885 |
| US-20100130420-A1 | NOVEL CHIMERIC LIGAND-GATED ION CHANNELS AND METHODS OF USE THEREOF | CHRNA7, CHRNA5, CHRNA4 | ENPP2 643/4885LPL 3659/4885LIPG 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.